30 April 2020 | News | By Ankit Kankar
The Phase 1 trial of NVX-CoV2373 is expected to begin in May with preliminary immunogenicity and safety results in July
In one of the first COVID-19 clinical vaccine trials, US-based clinical-stage biotechnology company Novavax has selected Australian speciality laboratory 360biolabs, to conduct sample analysis for the clinical trial of its SARS-CoV-2 recombinant spike protein nanoparticle vaccine, NVX-CoV2373.
Due to the nature and sensitivities of certain assays used in this clinical trial, a specialist biosecurity facility is required. With its highly experienced scientists working in state of the art Biosafety Level 2 (BSL-2) and 3 (BSL-3) laboratories, 360biolabs has the ideal resources and environment to conduct these crucial studies.
“We are thrilled that an organization with the reputation and capabilities of 360biolabs agreed to work with us in this critical clinical trial”, said Gregory Glenn, Novavax President of Research and Development. “We are confident 360biolabs will provide timely and appropriate data results”.
As Australia’s only ISO accredited, clinical services organisation, currently working with SARS-CoV-2, 360biolabs have received global requests for antiviral testing and clinical trial support. 360biolabs’ wealth of knowledge in the respiratory virus antiviral discovery and clinical space, ensures the team will delivery high quality, robust and reliable data.
The Phase 1 trial of NVX-CoV2373 is expected to begin in May with preliminary immunogenicity and safety results in July.
With fast start-up processes, quality data recognised by global regulatory bodies and 43.5% R&D tax incentive for eligible companies, Australia is known globally as a destination for early phase clinical trials.